Ignite Creation Date:
2024-05-05 @ 12:04 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00234065
Status:
COMPLETED
Last Update Posted:
2011-06-10
First Post:
2005-10-04
Brief Title:
Post-marketing Study of Cilostazol Cilostazol Stroke Prevention Study 2
Sponsor:
Otsuka Pharmaceutical Co Ltd
Organization:
Otsuka Pharmaceutical Co Ltd
Study Overview
Official Title:
Post-marketing Study of Cilostazol Study to Confirm Efficacy in Preventing Recurrent Cerebral Infarction in Comparison With Aspirin
Status:
COMPLETED
Status Verified Date:
2011-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to investigate the efficacy of cilostazol in preventing recurrence of cerebral infarction and the safety of long-term administration of the drug 100 mg twice daily in patients with cerebral infarction excluding cardiogenic cerebral embolism in a multi-center double-blind parallel-group comparison with aspirin 81 mg once daily
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| UMIN-CTR-C000000129 | None | None | None |
| JapicCTI-050034 | None | None | None |